ACAD vs. ABBV
ACAD (ACADIA Pharmaceuticals Inc.) and ABBV (AbbVie Inc.) are both stocks. Both are in the Healthcare sector — ACAD in Biotechnology, ABBV in Drug Manufacturers - General. Over the past 10 years, ACAD returned -5.07%/yr vs 17.56%/yr for ABBV. At a 0.27 correlation, their price movements are largely independent.
Performance
ACAD vs. ABBV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ACAD achieves a -19.77% return, which is significantly lower than ABBV's -3.41% return. Over the past 10 years, ACAD has underperformed ABBV with an annualized return of -5.07%, while ABBV has yielded a comparatively higher 17.56% annualized return.
ACAD
- 1D
- 2.58%
- 1M
- -3.42%
- YTD
- -19.77%
- 6M
- -17.19%
- 1Y
- -2.50%
- 3Y*
- -4.51%
- 5Y*
- -1.99%
- 10Y*
- -5.07%
ABBV
- 1D
- 0.80%
- 1M
- 4.31%
- YTD
- -3.41%
- 6M
- -4.15%
- 1Y
- 19.73%
- 3Y*
- 20.88%
- 5Y*
- 18.44%
- 10Y*
- 17.56%
ACAD vs. ABBV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ACAD ACADIA Pharmaceuticals Inc. | -19.77% | 45.56% | -41.39% | 96.67% | -31.79% | -56.34% | 24.96% | 164.56% | -46.30% | 4.40% |
ABBV AbbVie Inc. | -3.41% | 33.08% | 18.86% | -0.23% | 24.01% | 32.43% | 27.72% | 1.47% | -0.96% | 60.07% |
Correlation
The correlation between ACAD and ABBV is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Jan 3, 2013 | 0.27 |
The correlation between ACAD and ABBV shifts across timeframes, from 0.16 (3 years) to 0.27 (all time), reflecting how their relationship changes across market environments.
Fundamentals
ACAD:
$3.70B
ABBV:
$385.19B
ACAD:
$2.20
ABBV:
$2.05
ACAD:
9.75
ABBV:
105.79
ACAD:
3.34
ABBV:
6.13
ACAD:
2.97
ABBV:
14.01
ACAD:
$1.10B
ABBV:
$62.82B
ACAD:
$758.58M
ABBV:
$46.15B
ACAD:
$104.56M
ABBV:
$17.96B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ACAD vs. ABBV — Risk / Return Rank
ACAD
ABBV
ACAD vs. ABBV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ACAD | ABBV | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.07 | 0.83 | -0.90 |
Sortino ratioReturn per unit of downside risk | 0.17 | 1.30 | -1.13 |
Omega ratioGain probability vs. loss probability | 1.02 | 1.16 | -0.14 |
Calmar ratioReturn relative to maximum drawdown | -0.09 | 1.14 | -1.24 |
Martin ratioReturn relative to average drawdown | -0.17 | 2.57 | -2.74 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ACAD | ABBV | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.07 | 0.83 | -0.90 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.04 | 0.81 | -0.85 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.08 | 0.68 | -0.77 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.06 | 0.73 | -0.67 |
Drawdowns
ACAD vs. ABBV - Drawdown Comparison
The maximum ACAD drawdown since its inception was -96.29%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for ACAD and ABBV.
Loading charts...
Drawdown Indicators
| ACAD | ABBV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.29% | -45.09% | -51.20% |
Max Drawdown (1Y)Largest decline over 1 year | -27.58% | -17.32% | -10.26% |
Max Drawdown (3Y)Largest decline over 3 years | -57.87% | -20.74% | -37.13% |
Max Drawdown (5Y)Largest decline over 5 years | -57.87% | -21.92% | -35.95% |
Max Drawdown (10Y)Largest decline over 10 years | -77.18% | -45.09% | -32.09% |
Current DrawdownCurrent decline from peak | -62.40% | -9.04% | -53.36% |
Average DrawdownAverage peak-to-trough decline | -50.15% | -10.73% | -39.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.70% | 7.69% | +7.01% |
Volatility
ACAD vs. ABBV - Volatility Comparison
ACADIA Pharmaceuticals Inc. (ACAD) has a higher volatility of 10.49% compared to AbbVie Inc. (ABBV) at 5.42%. This indicates that ACAD's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ACAD | ABBV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.49% | 5.42% | +5.07% |
Volatility (6M)Calculated over the trailing 6-month period | 26.13% | 17.61% | +8.52% |
Volatility (1Y)Calculated over the trailing 1-year period | 36.89% | 23.96% | +12.93% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 55.51% | 22.84% | +32.67% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 62.09% | 25.74% | +36.35% |
Dividends
ACAD vs. ABBV - Dividend Comparison
ACAD has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.10%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABBV AbbVie Inc. | 3.10% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
ACAD ACADIA Pharmaceuticals Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
ACAD vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between ACADIA Pharmaceuticals Inc. and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ACAD vs. ABBV - Profitability Comparison
ACAD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported a gross profit of 0.00 and revenue of 268.06M. Therefore, the gross margin over that period was 0.0%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.
ACAD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported an operating income of -4.62M and revenue of 268.06M, resulting in an operating margin of -1.7%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.
ACAD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported a net income of 3.64M and revenue of 268.06M, resulting in a net margin of 1.4%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.
Frequently Asked Questions
ACAD and ABBV have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ACAD has higher volatility (10.49%) compared to ABBV (5.42%). In terms of maximum drawdown, ACAD dropped -96.29% vs ABBV's -45.09%.
ABBV currently has the higher Sharpe Ratio (0.83 vs -0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ACAD and ABBV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer